{"organizations": [], "uuid": "77d5cfc18b425086803c84ad8b2d03840397028c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "https://www.reuters.com/finance/funds", "section_title": "Best Mutual Funds and ETFs | Reuters.com", "url": "https://www.reuters.com/article/brief-clarus-lifesciences-ii-lp-reports/brief-clarus-lifesciences-ii-lp-reports-a-6-92-pct-stake-in-catabasis-pharmaceuticals-as-of-march-22-idUSFWN1RH0L5", "country": "US", "domain_rank": 408, "title": "BRIEF-Clarus Lifesciences II Lp Reports A 6.92 Pct Stake In Catabasis Pharmaceuticals As Of March 22", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.553, "site_type": "news", "published": "2018-04-05T04:53:00.000+03:00", "replies_count": 0, "uuid": "77d5cfc18b425086803c84ad8b2d03840397028c"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-clarus-lifesciences-ii-lp-reports/brief-clarus-lifesciences-ii-lp-reports-a-6-92-pct-stake-in-catabasis-pharmaceuticals-as-of-march-22-idUSFWN1RH0L5", "ord_in_thread": 0, "title": "BRIEF-Clarus Lifesciences II Lp Reports A 6.92 Pct Stake In Catabasis Pharmaceuticals As Of March 22", "locations": [], "entities": {"persons": [], "locations": [{"name": "catabasis", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "catabasis pharmaceuticals inc", "sentiment": "negative"}, {"name": "sec", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 4 (Reuters) - Catabasis Pharmaceuticals Inc:\n* CLARUS LIFESCIENCES II LP REPORTS A 6.92 PCT STAKE IN CATABASIS PHARMACEUTICALS INC AS OF MARCH 22 - SEC FILING\n* CLARUS LIFESCIENCES II LP PREVIOUSLY REPORTED A 11.92 PERCENT STAKE IN CATABASIS PHARMACEUTICALS AS OF OCT. 31, 2017 Source text for Eikon: ( bit.ly/2JjI0wt ) Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "https://bit.ly/2JjI0wt", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-05T04:53:00.000+03:00", "crawled": "2018-04-05T00:13:45.022+03:00", "highlightTitle": ""}